An intravenous biological therapy for psoriasis: Infliximab

Authors

  • M Mathur Department of Dermatology, College of Medical Sciences, Bharatpur, Chitwan District
  • SK Kedia Department of Dermatology, College of Medical Sciences, Bharatpur, Chitwan District
  • RBK Chimire Department of Dermatology, College of Medical Sciences, Bharatpur, Chitwan District

DOI:

https://doi.org/10.3126/jcmsn.v7i1.5977

Keywords:

Infliximab, monoclonal antibody, dex, quality of life.

Abstract

Psoriasis is a common, chronic inflammatory skin disease which typically follows a relapsing and remitting course and is associated with joint disease. The significant reduction in quality of life and the psychosocial disability suffered by patients underline the need for prompt, effective treatment and long-term disease control. Patients with moderate to severe disease often require systemic treatment with effective & new modalities such as biological-Infliximab. Review will highlight fundamental aspects of infliximab and its use in Psoriasis as well as provide specific comments regarding this monoclonal antibody and its position in of psoriasis in the future treatment.

DOI: http://dx.doi.org/10.3126/jcmsn.v7i1.5977

JCMSN 2011; 7(1): 69-72

Downloads

Download data is not yet available.
Abstract
595
PDF
617

Downloads

Published

2012-03-03

How to Cite

Mathur, M., Kedia, S., & Chimire, R. (2012). An intravenous biological therapy for psoriasis: Infliximab. Journal of College of Medical Sciences-Nepal, 7(1), 69–72. https://doi.org/10.3126/jcmsn.v7i1.5977

Issue

Vol. 7 No. 1 (2011)

Section

Review Articles

License

This license enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.